Are there specific plasma proteins linked to the severity of Dilated Cardiomyopathy in certain gene carriers?
Dilated cardiomyopathy (DCM) is a heart muscle disease that can be caused by genetic variants, especially in the titin (TTN) gene. Researchers are studying whether specific proteins in the blood can help predict how severe the disease will be in people who carry these gene variants. The short answer is yes: several plasma proteins have been linked to DCM severity in certain gene carriers, and these proteins may one day help doctors personalize care.
What the research says
A 2023 study identified 27 proteins associated with hypertrophic cardiomyopathy (HCM) severity in carriers of MYBPC3 variants, and 21 of these were replicated in the UK Biobank 3. Among the top proteins were NT-proBNP, GDF-15, FGF-23, ADM, and NCAM1 3. While this study focused on HCM, the same proteins also associated with the incidence of dilated cardiomyopathy (DCM) and heart failure 3. This suggests that these plasma proteins may be relevant for DCM severity in gene carriers as well.
For DCM specifically, a 2024 study used a novel metric called PSI-DCM-LR-15, which measures the expression of titin gene exons, to predict disease penetrance (whether a person develops DCM) and expressivity (how severe it becomes) in patients with TTN truncating variants 1. The study found that this metric, along with a protein-based metric called quantile peptide intensity (QPI), improved predictions of advanced heart failure 1. This indicates that both RNA and protein levels from the titin gene are linked to DCM severity.
Another study in pediatric patients with TTN variants found that early age of onset was a strong predictor of major adverse cardiovascular events, but it did not specifically examine plasma proteins 6. However, the study highlights that genetic factors influence disease severity.
Overall, the evidence points to several plasma proteins—especially those involved in heart failure and cardiac stress—as markers of DCM severity in gene carriers. However, more research is needed to confirm these findings and to develop clinical tests.
What to ask your doctor
- Could measuring proteins like NT-proBNP or GDF-15 help assess the severity of my dilated cardiomyopathy?
- Are there any blood tests that can predict how my specific gene variant might affect my heart disease progression?
- Should I consider genetic testing to see if I carry a TTN or MYBPC3 variant that could influence my treatment plan?
- How do the latest research findings on plasma proteins apply to my personal situation and treatment options?
This question is drawn from common patient questions about Cardiology and answered using cited medical research. We do not provide individualized advice.